Targeting CD40L: a promising therapeutic approach
- PMID: 15242934
- PMCID: PMC440614
- DOI: 10.1128/CDLI.11.4.635-641.2004
Targeting CD40L: a promising therapeutic approach
References
-
- Aruffo, A., M. Farrington, D. Hollenbaugh, X. Li, A. Milatovich, S. Nonoyama, J. Bajorath, L. S. Grosmaire, R. Stenkamp, and M. Neubauer. 1993. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 72:291-300. - PubMed
-
- Boumpas, D. T., R. Furie, S. Manzi, G. G. Illei, D. J. Wallace, J. E. Balow, and A. Vaishnaw. 2003. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48:719-727. - PubMed
-
- Buchner, K., V. Henn, M. Grafe, O. J. de Boer, A. E. Becker, and R. A. Kroczek. 2003. CD40 ligand is selectively expressed on T cells and platelets: implications for CD40-CD40L signaling in atherosclerosis. J. Pathol. 201:288-295. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
